Hemostasis Using Radiofrequency Ablation for Track Bleeding

Hemostasis Using Radiofrequency Ablation for Track Bleeding After Liver Biopsy

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05017350

Enrollment

Registered

2021-08-23

Start date

2021-07-01

Completion date

2024-12-31

Last updated

2021-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding

Keywords

liver, track bleeding, radiofrequency ablation

Brief summary

This study aims to evaluate the usefulness of hemostasis using radiofrequency ablation for track bleeding that has occurred after percutaneous biopsy of the liver.

Detailed description

Purpose: To evaluate the usefulness of hemostasis using radiofrequency ablation for track bleeding after percutaneous liver biopsy. Method: * Enroll patients who continue to bleed despite conservative treatment for track bleeding that has occurred after liver biopsy. * Radiofreqeuncy ablation: Under monitoring vital signs and controlling pain with intravenous agents, the electrode is inserted into the bleeding focus. The bleeding focus is ablated. * Hemostasis is evaluated by ultrasound (right after radiofrequency ablation), CT scan (after the radiofrequency ablation), and ultrasound (the day after radiofrequency ablation) * If hemostasis fails using radiofrequency ablation, transarterial hepatic embolization is performed immediately.

Interventions

PROCEDUREradiofrequency ablation

Under the ultrasound guidance, the electrode is inserted into the bleeding focus of the liver and the bleeding focus is ablated.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 79 Years

Healthy volunteers

Inclusion criteria

* Ultrasound guided percutaneous liver biopsy at Samsung Medical Center * Track bleeding after biopsy * Persistent track bleeding even after conservative management * Consent to this study

Exclusion criteria

* Not consent to this study * \<20 years old or \>=80 years old * Contraindication to radiofrequency ablation * Radiofrequency ablation for track bleeding is not technically possible. * Unstable vital signs

Design outcomes

Primary

Measure	Time frame	Description
hemostasis rate	immediately after radiofrequency ablation	success rate of hemostasis using radiofrequency ablation on CT taken after radiofrequency ablation

Secondary

Measure	Time frame	Description
complication rate	immediately after radiofrequency ablation	complication rate associated with radiofrequency ablation on CT taken after radiofrequency ablation

Countries

South Korea

Contacts

Primary ContactKyoung Doo Song, Professor

kd3893.song@samsung.com82-2-3410-2518

Backup ContactMin Woo Lee, Professor

mw2542.lee@samsung.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026